Clinical-stage. GMP manufactured. Human safety data in hand. ODD, RPDD, and Priority Review Voucher are the planned regulatory levers — none filed or granted yet. Licensed from Sapu Biosciences into PDAOAI — neurology and longevity fields only. Sapu retains worldwide oncology.
PDAOAI's SAPU003 franchise covers two fields only: rare pediatric neurology (mTORopathies) and healthy aging / longevity. Oncology remains with Sapu Biosciences worldwide. Addressable population across neurology: ~92,000 US, roughly 180,000 across US + EU5.
| Indication | Tier | Prevalence | Patients (US) |
|---|---|---|---|
| Tuberous Sclerosis Complex (TSC) | Tier 1 | ~1:6,000 | ~56,000 |
| Focal Cortical Dysplasia (FCD) | Tier 1 | ~1:25,000 | ~14,000 |
| DEPDC5-associated epilepsy | Tier 2 | ~1:50,000 | ~7,000 |
| NPRL2 / NPRL3 disorders | Tier 2 | Ultra rare | <5,000 |
| GATORopathies | Tier 2 | Ultra rare | <5,000 |
| MTOR gain-of-function syndromes | Tier 2 | Ultra rare | <5,000 |
The biology holds together at three levels: mTOR as the root, KCC2 as the downstream chloride cotransporter, and GABAergic signaling as the clinical readout.
mTOR pathway dysregulation drives multiple pediatric epilepsy syndromes across the mTORopathy spectrum. Both mTORC1 and mTORC2 signaling implicated.
mTOR hyperactivation impairs KCC2, the neuronal chloride cotransporter. Chloride accumulates inside neurons. GABA — the brain's main inhibitory signal — flips from calming to excitatory. Neurons fire uncontrolled. Seizures.
SAPU003 inhibits mTOR → restores KCC2 function → normalizes chloride homeostasis → GABA regains its inhibitory role → seizures suppressed. Reference: Bakouh N, et al. Brain 2025;148(2):549-567.
Oral everolimus is FDA-approved and works — for the indications where oral delivery is sufficient. SAPU003 is the intravenous nanoparticle reformulation that changes the pharmacokinetics.
| Feature | SAPU003 (IV nanoparticle) | Oral rapalogs (Afinitor) |
|---|---|---|
| Route | Intravenous | Oral |
| GI absorption | Bypassed | Variable |
| First-pass metabolism | Bypassed | Significant |
| Food effect | None | Yes |
| Onset / exposure | Rapid | Slower / variable |
| Drug interactions | Reduced | High (CYP3A / P-gp) |
| Dosing paradigm | Intermittent | Continuous daily |
| Chronic GI exposure | Minimized | Persistent |
| Microbiome impact | Lower risk | Higher risk |
None of these designations have been filed or granted yet. This is the pathway the IND-enabling program is targeting — the three regulatory levers that make a small-population pediatric neurology asset economically meaningful.
Target: file ODD applications for Tier 1 mTORopathies (TSC, FCD) once IND-enabling data supports it. If granted, ODD carries 7-year U.S. market exclusivity, tax credits, and development incentives for the qualifying rare indication.
Target: file Rare Pediatric Disease Designation to qualify for a Priority Review Voucher on approval. Recent Priority Review Vouchers have sold at $150–200M (Jazz Pharmaceuticals: $200M, Jan 2026). Program reauthorized through September 2029. Optionality only — not booked value.
Pediatric exclusivity extension (6 months) and Breakthrough / Accelerated Approval pathways are available for high-unmet-need pediatric neurology. Eligibility to be established on the biomarker package generated in the IND-enabling program.
The IND-enabling program is organized to accelerate biomarker data on existing clinical patients while running parallel translational and regulatory work.
Timeline: Immediate. Collection and analysis on existing clinical SAPU003 patients — PBMCs, plasma, exosomes, cfDNA, cytokine panels. Every patient generates biomarker data that would otherwise take years and millions in a separate program.
Timeline: 6–12 months. ODD and RPDD applications for Tier 1 mTORopathies (TSC, FCD). Natural history review. Regulatory briefing package. Development roadmap.
Timeline: 6–18 months. Focused preclinical studies on three questions: does SAPU003 restore KCC2 function; does it normalize chloride homeostasis; can KCC2 serve as a predictive biomarker for patient selection.
Timeline: 6–12 months. PK modeling, CNS penetration studies, exposure-response modeling. Establishes SAPU003's primary differentiation vs. oral rapalogs quantitatively.
Compound IP, the Deciparticle™ nanoparticle platform, and worldwide oncology rights.
Exclusive worldwide development and commercial rights across the neurology and longevity fields. Structured on standard field-license economics.
The second program run through the same 24-month discovery cycle. Docetaxel is an approved active; the innovation is delivery. Sub-20 nm Deciparticle™ nanoparticles eliminate the polysorbate excipients conventional taxane delivery requires, which are responsible for much of the hypersensitivity and premedication burden.